Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00390260
Other study ID # 0966-179
Secondary ID 2006_535
Status Completed
Phase Phase 3
First received October 18, 2006
Last updated January 31, 2017
Start date February 2002
Est. completion date February 2003

Study information

Verified date January 2017
Source Merck Sharp & Dohme Corp.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study the effect of rofecoxib 50 mg compared to both placebo, and hydrocodone 7.5 mg with acetaminophen 750 mg, to treat moderate to severe pain following arthroscopic knee surgery.


Recruitment information / eligibility

Status Completed
Enrollment 420
Est. completion date February 2003
Est. primary completion date February 2003
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Elective outpatient arthroscopic knee surgery expected to last <= 90 minutes using general anesthesia

- Patients must experience moderate to severe pain following surgery

- Patient must be in general good health as judged by the primary investigator

Exclusion Criteria:

- Osteoarthritis; rheumatoid arthritis

- Allergy/sensitivity to aspirin, ibuprofen, indomethacin, other NSAIDs, COX-2 inhibitors (e.g., rofecoxib, celecoxib), hydrocodone, acetaminophen

- Asthma associated with nasal polyps

- Any arthroscopic knee surgery in the past 6 months

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MK0966 / Duration of Treatment: 1 Days

Comparator: acetaminophen (+) hydrocodone bitartrate / Duration of Treatment: 1 Days

Comparator: placebo (unspecified) / Duration of Treatment: 1 Days


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme Corp.

References & Publications (1)

Chelly JE, Nissen CW, Rodgers AJ, Smugar SS, Tershakovec AM. The efficacy of rofecoxib 50 mg and hydrocodone/acetaminophen 7.5/750 mg in patients with post-arthroscopic pain. Curr Med Res Opin. 2007 Jan;23(1):195-206. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Total Pain Relief over 6 hours following a single oral dose compared to placebo. 6 hours
Secondary Total Pain Relief over 6 hours following a single oral dose compared to hydrocodone + acetaminophen. 6 hours